4-[(tert-butoxycarbonyl)amino]-1,3-thiazole-5-carboxylic acid | 909404-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[(tert-butoxycarbonyl)amino]-1,3-thiazole-5-carboxylic acid
• 英文别名: 4-((tert-Butoxycarbonyl)amino)thiazole-5-carboxylic acid；4-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazole-5-carboxylic acid
• CAS: 909404-02-0
• 化学式: C₉H₁₂N₂O₄S
• 分子量: 244.271
• InChiKey: BVTAYGYNFOKXDS-UHFFFAOYSA-N

物化性质

• 沸点：
  353.9±27.0 °C(Predicted)
• 密度：
  1.406±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-氨基-2,2-二氟-1,3-苯并二噁唑 、 4-[(tert-butoxycarbonyl)amino]-1,3-thiazole-5-carboxylic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 tert-butyl (5-{(2,2-difluoro-1,3-benzodioxol-5-yl)aminocarbonyl}-1,3-thiazol-4-yl)carbamate
  参考文献：
  名称：

  WO2006/96338

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 4-(bis(tert-butoxycarbonyl)amino)thiazole-5-carboxylate 在 sodium hydroxide 、 乙醇 、 水 、 potassium dihydrogenphosphate 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以96%的产率得到4-[(tert-butoxycarbonyl)amino]-1,3-thiazole-5-carboxylic acid
  参考文献：
  名称：

  WO2006/96338

  摘要：

  公开号：

文献信息

• 1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents
  申请人：Chuang Chih-Yuan

  公开号：US20090023753A1

  公开（公告）日：2009-01-22

  This invention relates to novel 1,3-thiazole-5-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.

  本发明涉及新颖的1,3-噻唑-5-羧酰胺化合物，包含这些化合物的制药组合物，以及将这些化合物或组合物用作癌症化疗药剂的用途。
• INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA
  申请人：White Stephen L.

  公开号：US20110021541A1

  公开（公告）日：2011-01-27

  Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.

  本发明揭示了抑制PI3Kδ活性的化合物，包括选择性抑制PI3Kδ活性的化合物。本发明还揭示了抑制磷脂酰肌醇3-激酶δ亚型（PI3Kδ）活性的方法，以及使用这些化合物治疗疾病的方法，例如免疫和炎症紊乱，其中PI3Kδ在白细胞功能中发挥作用。
• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：EP4038066A1

  公开（公告）日：2022-08-10
• [EN] INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA<br/>[FR] INHIBITEURS DE PHOSPHATIDYL-INOSITOL 3-KINASE DELTA HUMAINE
  申请人：LILLY CO ELI

  公开号：WO2009064802A2

  公开（公告）日：2009-05-22

  Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.
• [EN] BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT BRM ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2021067606A1

  公开（公告）日：2021-04-08

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.